These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 31376250)

  • 1. Monotherapy is a relevant option in rheumatoid arthritis treatment: a literature review.
    Doria A; Zavaglia D
    Clin Exp Rheumatol; 2019; 37(5):862-871. PubMed ID: 31376250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
    Smolen JS; Landewé RBM; Bijlsma JWJ; Burmester GR; Dougados M; Kerschbaumer A; McInnes IB; Sepriano A; van Vollenhoven RF; de Wit M; Aletaha D; Aringer M; Askling J; Balsa A; Boers M; den Broeder AA; Buch MH; Buttgereit F; Caporali R; Cardiel MH; De Cock D; Codreanu C; Cutolo M; Edwards CJ; van Eijk-Hustings Y; Emery P; Finckh A; Gossec L; Gottenberg JE; Hetland ML; Huizinga TWJ; Koloumas M; Li Z; Mariette X; Müller-Ladner U; Mysler EF; da Silva JAP; Poór G; Pope JE; Rubbert-Roth A; Ruyssen-Witrand A; Saag KG; Strangfeld A; Takeuchi T; Voshaar M; Westhovens R; van der Heijde D
    Ann Rheum Dis; 2020 Jun; 79(6):685-699. PubMed ID: 31969328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis.
    Kerschbaumer A; Sepriano A; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; McInnes IB; Bijlsma JWJ; Burmester GR; de Wit M; Falzon L; Landewé R
    Ann Rheum Dis; 2020 Jun; 79(6):744-759. PubMed ID: 32033937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
    Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
    RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review.
    Emery P; Pope JE; Kruger K; Lippe R; DeMasi R; Lula S; Kola B
    Adv Ther; 2018 Oct; 35(10):1535-1563. PubMed ID: 30128641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry.
    Olsen IC; Lie E; Vasilescu R; Wallenstein G; Strengholt S; Kvien TK
    Rheumatology (Oxford); 2019 Mar; 58(3):481-491. PubMed ID: 30508189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Kerschbaumer A; Sepriano A; Bergstra SA; Smolen JS; van der Heijde D; Caporali R; Edwards CJ; Verschueren P; de Souza S; Pope JE; Takeuchi T; Hyrich KL; Winthrop KL; Aletaha D; Stamm TA; Schoones JW; Landewé RBM
    Ann Rheum Dis; 2023 Jan; 82(1):95-106. PubMed ID: 36368906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
    Smolen JS; Landewé R; Bijlsma J; Burmester G; Chatzidionysiou K; Dougados M; Nam J; Ramiro S; Voshaar M; van Vollenhoven R; Aletaha D; Aringer M; Boers M; Buckley CD; Buttgereit F; Bykerk V; Cardiel M; Combe B; Cutolo M; van Eijk-Hustings Y; Emery P; Finckh A; Gabay C; Gomez-Reino J; Gossec L; Gottenberg JE; Hazes JMW; Huizinga T; Jani M; Karateev D; Kouloumas M; Kvien T; Li Z; Mariette X; McInnes I; Mysler E; Nash P; Pavelka K; Poór G; Richez C; van Riel P; Rubbert-Roth A; Saag K; da Silva J; Stamm T; Takeuchi T; Westhovens R; de Wit M; van der Heijde D
    Ann Rheum Dis; 2017 Jun; 76(6):960-977. PubMed ID: 28264816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Nam JL; Ramiro S; Gaujoux-Viala C; Takase K; Leon-Garcia M; Emery P; Gossec L; Landewe R; Smolen JS; Buch MH
    Ann Rheum Dis; 2014 Mar; 73(3):516-28. PubMed ID: 24399231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry.
    Gabay C; Riek M; Scherer A; Finckh A;
    Rheumatology (Oxford); 2015 Sep; 54(9):1664-72. PubMed ID: 25922549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Chatzidionysiou K; Emamikia S; Nam J; Ramiro S; Smolen J; van der Heijde D; Dougados M; Bijlsma J; Burmester G; Scholte M; van Vollenhoven R; Landewé R
    Ann Rheum Dis; 2017 Jun; 76(6):1102-1107. PubMed ID: 28356243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Nam JL; Takase-Minegishi K; Ramiro S; Chatzidionysiou K; Smolen JS; van der Heijde D; Bijlsma JW; Burmester GR; Dougados M; Scholte-Voshaar M; van Vollenhoven R; Landewé R
    Ann Rheum Dis; 2017 Jun; 76(6):1113-1136. PubMed ID: 28283512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
    Smolen JS; Landewé RBM; Bergstra SA; Kerschbaumer A; Sepriano A; Aletaha D; Caporali R; Edwards CJ; Hyrich KL; Pope JE; de Souza S; Stamm TA; Takeuchi T; Verschueren P; Winthrop KL; Balsa A; Bathon JM; Buch MH; Burmester GR; Buttgereit F; Cardiel MH; Chatzidionysiou K; Codreanu C; Cutolo M; den Broeder AA; El Aoufy K; Finckh A; Fonseca JE; Gottenberg JE; Haavardsholm EA; Iagnocco A; Lauper K; Li Z; McInnes IB; Mysler EF; Nash P; Poor G; Ristic GG; Rivellese F; Rubbert-Roth A; Schulze-Koops H; Stoilov N; Strangfeld A; van der Helm-van Mil A; van Duuren E; Vliet Vlieland TPM; Westhovens R; van der Heijde D
    Ann Rheum Dis; 2023 Jan; 82(1):3-18. PubMed ID: 36357155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
    Leong JWY; Cheung PP; Dissanayake S; Fong WWS; Leong KH; Leung YY; Lim AYN; Lui NL; Manghani M; Santosa A; Sriranganathan MK; Suresh E; Tan TC; Teng GG; Lahiri M
    Int J Rheum Dis; 2020 Feb; 23(2):140-152. PubMed ID: 31859424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry.
    Jørgensen TS; Turesson C; Kapetanovic M; Englund M; Turkiewicz A; Christensen R; Bliddal H; Geborek P; Kristensen LE
    PLoS One; 2017; 12(2):e0169946. PubMed ID: 28151971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.
    An Y; Liu T; He D; Wu L; Li J; Liu Y; Bi L; Zhou B; Lin C; He L; Liu X; Li X; Yang N; Zhang Z; Song H; Wei W; Liu J; Bi Y; Li Z
    Clin Rheumatol; 2017 Jan; 36(1):35-43. PubMed ID: 27709444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world treatment persistence in patients with rheumatoid arthritis initiating DMARDs in Germany-a health insurance claims data analysis.
    Fiehn C; Zinke S; Haas JS; Meise D; Theil J; Gurrath M; Orzechowski HD
    Z Rheumatol; 2023 Nov; 82(9):739-753. PubMed ID: 36757417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.
    Smolen JS; Landewé R; Breedveld FC; Buch M; Burmester G; Dougados M; Emery P; Gaujoux-Viala C; Gossec L; Nam J; Ramiro S; Winthrop K; de Wit M; Aletaha D; Betteridge N; Bijlsma JW; Boers M; Buttgereit F; Combe B; Cutolo M; Damjanov N; Hazes JM; Kouloumas M; Kvien TK; Mariette X; Pavelka K; van Riel PL; Rubbert-Roth A; Scholte-Voshaar M; Scott DL; Sokka-Isler T; Wong JB; van der Heijde D
    Ann Rheum Dis; 2014 Mar; 73(3):492-509. PubMed ID: 24161836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Sepriano A; Kerschbaumer A; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; McInnes IB; Bijlsma JW; Burmester GR; de Wit M; Falzon L; Landewé R
    Ann Rheum Dis; 2020 Jun; 79(6):760-770. PubMed ID: 32033941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignancies and rheumatoid arthritis, csDMARDs, biological DMARDs, and JAK inhibitors: challenge and outlook.
    Sonomoto K; Tanaka Y
    Expert Rev Clin Immunol; 2023; 19(11):1325-1342. PubMed ID: 37578325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.